Xultophy 100/3.6 for the Treatment of Type 2 Diabetes

Developed by Novo Nordisk, Xultophy 100/3.6 is indicated for the treatment of type 2 diabetes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news